That is the goal. Even a small royalty on sales of Botox in certain indications could be worth a lot to RVNC.
If it were up to me, I might have conducted non-inferiority phase-3 trials against Botox with a superiority test on duration of effect. However, this would have entailed a risk of missing the superiority threshold, which could have been perceived by investors as a sort of failure. Inasmuch as RT002 doesn't actually have to be better than Botox to succeed in the marketplace, the placebo comparator may be preferable.
I've ruled out all neuropsychiatric indications (too difficult to prove efficacy), and I'm still pondering whether such indications as plantar fasciitis and TMJ are sufficiently "exciting." The mystery indication might not be related to the IP package acquired from Dr. Borodic due to the recency of that IP deal and the amount of preparatory work typically required before starting a phase-2 trial in a new indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.